★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Zoetis Inc. (ZTS) Moat Analysis
Zoetis Inc.
ZTS · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Zoetis is a global animal health company with most revenue from companion animal products and a significant livestock portfolio. Its best-supported advantages are veterinarian and technical field support, brand loyalty, product IP and complex livestock manufacturing capacity. Q1 2026 revenue still skewed toward companion animal products, but U.S. companion animal sales fell amid price sensitivity, competition and generic entry while livestock grew. Zoetis also has a pending acquisition of Neogen’s animal-genomics business, expected to close in the second half of 2026. Competitive pressure comes from generic alternatives, clinic and distributor consolidation, and growing retail/e-commerce buyer power.
Primary segment
Companion Animal Products
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
3 segments · 6 tags
Updated 2026-07-12
Segments
Companion Animal Products
Companion animal veterinary medicines, vaccines and diagnostics
Revenue
67.2%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Livestock Products
Livestock animal health medicines and vaccines (cattle, swine, poultry, aquaculture)
Revenue
31.8%
Structure
Oligopoly
Pricing
weak
Share
—
Peers
Client Supply Services & Human Health
Contract manufacturing services (animal health) and limited human health products
Revenue
1%
Structure
Competitive
Pricing
weak
Share
—
Peers
—
Moat Claims
Companion Animal Products
Companion animal veterinary medicines, vaccines and diagnostics
Revenue share derived from Zoetis Q1 2026 results release (filed on Form 8-K 2026-05-07): Companion Animal revenue $1,519M of $2,262M total revenue.
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Quality/safety and veterinarian trust drive persistent brand loyalty, reducing willingness to switch.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Loss of exclusivity and generic/biosimilar entry
- Adverse-event publicity or label changes harming trust
- Channel shift toward powerful retailers and e-commerce
Leading indicators
- Price/mix contribution in companion animal revenue
- Veterinarian recommendation rates for key franchises
- Adverse-event reports / regulatory communications
Counterarguments
- Clinically similar alternatives can win on price or availability
- Large rivals can outspend on marketing and medical education
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
Large salesforce plus veterinary/technical specialists create high-touch support that improves adoption and retention in clinics.
Service Field Network moat: definition, examples, and stocks
Erosion risks
- Clinic consolidation reduces value of rep relationships
- Competitors matching field coverage and specialist resources
- Digital channels partially substituting in-person support
Leading indicators
- Field headcount and veterinary specialist retention
- Sales per rep and coverage metrics
- Clinic group penetration (enterprise accounts won/lost)
Counterarguments
- Other global incumbents also run large field organizations
- Large corporate clinic groups may centralize purchasing and limit rep influence
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents/trademarks and (where applicable) regulatory data exclusivity protect differentiated products, but expirations invite aggressive generic competition.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent expirations / loss of exclusivity
- At-risk generic launches and patent challenges
- Pricing pressure via discounts/rebates vs generics
Leading indicators
- Products nearing loss of exclusivity (% of sales)
- Generic approval/launch activity in key markets
- Litigation outcomes and settlement terms
Counterarguments
- Generic entrants can rapidly erode share once protection ends
- Some therapies are substitutable across brands, limiting IP-based pricing power
Livestock Products
Livestock animal health medicines and vaccines (cattle, swine, poultry, aquaculture)
Revenue share derived from Zoetis Q1 2026 results release (filed on Form 8-K 2026-05-07): Livestock revenue $720M of $2,262M total revenue.
Capacity Moat
Supply
Capacity Moat
Strength
Durability
Confidence
Evidence
A large, regulated manufacturing footprint and complex processes (often sole-sourced) support reliable supply and speed-to-market for vaccines and pharmaceuticals.
Capacity Moat moat: definition, examples, and stocks
Erosion risks
- Manufacturing disruptions, quality deviations or key site outages
- Supply chain shocks impacting biological inputs
- Competitors expanding capacity in priority categories
Leading indicators
- Stock-out frequency in vaccines/biologics
- Batch rejection rates / quality metrics
- Capex levels and capacity expansion announcements
Counterarguments
- Large competitors also have global manufacturing footprints
- Reliance on third-party CMOs can reduce differentiation if competitors access the same CMOs
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
Technical and veterinary specialists support producers and veterinarians, improving protocol adoption and switching costs in herd/flock health programs.
Service Field Network moat: definition, examples, and stocks
Erosion risks
- Producer consolidation reduces the number of decision-makers
- Competitors offering comparable technical service
- Remote/digital advisory reducing differentiation
Leading indicators
- Account wins/losses among large producers and integrators
- Veterinary specialist retention and coverage
- Protocol adherence and repeat purchasing by large accounts
Counterarguments
- Integrated producers may prioritize price over service
- Competitors can bundle services with products in tenders
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Proven efficacy and safety in production settings sustains repeat purchasing, but price sensitivity is higher than in companion animal markets.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Producer focus on cost per dose and tendering
- Generic competition in mature categories
- Public policy/consumer pressure altering product mix
Leading indicators
- Gross margin trend in livestock portfolio
- Share of sales exposed to tenders/large accounts
- Regulatory restrictions affecting product classes
Counterarguments
- Many livestock categories are closer to commodity competition
- Bundling by competitors can outweigh brand preference
Client Supply Services & Human Health
Contract manufacturing services (animal health) and limited human health products
Revenue share derived from Zoetis Q1 2026 results release (filed on Form 8-K 2026-05-07): Contract Manufacturing & Human Health revenue $23M of $2,262M total revenue.
Insufficient segment-specific evidence to assign a moat claim.
Evidence
Quality and safety concerns... contribute to brand loyalty... brand loyalty continues even after loss of patent-based and regulatory exclusivity.
Direct support for brand-driven demand retention (pricing resilience + lower churn).
As of December 31, 2025, our sales organization consisted of approximately 4,150 employees.
Scale of field organization supports dense coverage and relationship advantages.
Our sales organization also includes technical and veterinary operations specialists... providing scientific consulting support.
Specialist support raises switching costs for practices and helps defend product protocols.
Our product portfolio enjoys the protection of more than 5,500 granted patents and 1,600 pending patent applications.
Shows large IP portfolio supporting exclusivity and differentiation.
We face competition from lower-priced generic alternatives to many of our products that no longer have patent protection.
Direct acknowledgment that IP protection is time-limited and contested.
Showing 5 of 10 sources.
Risks & Indicators
Erosion risks
- Loss of exclusivity and generic/biosimilar entry
- Adverse-event publicity or label changes harming trust
- Channel shift toward powerful retailers and e-commerce
- Clinic consolidation reduces value of rep relationships
- Competitors matching field coverage and specialist resources
- Digital channels partially substituting in-person support
Leading indicators
- Price/mix contribution in companion animal revenue
- Veterinarian recommendation rates for key franchises
- Adverse-event reports / regulatory communications
- Share of sales from products approaching loss of exclusivity
- Field headcount and veterinary specialist retention
- Sales per rep and coverage metrics
Research ZTS elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.